Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (TSE:APS)
TSX:APS
APS Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.98 - C$60.90
Previous CloseN/A
Volume48.76K
Average Volume (3M)5.32K
Market Cap
$7.43M
Enterprise ValueC$25.21M
Total Cash (Recent Filing)$844.83K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.53
Next Earnings
May 12, 2025EPS Estimate
-3.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-63.90
Shares Outstanding2,552,429
10 Day Avg. Volume11,987
30 Day Avg. Volume5,316
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap3.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.70
Forecast
1Y Price Target
C$12.89Price Target Upside342.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Aptose Biosciences News
PremiumCompany Announcements
Aptose Biosciences Advances AML Therapy with Promising Results
PremiumCompany Announcements
Aptose Biosciences to Delist from Nasdaq in April
PremiumCompany Announcements
Aptose Biosciences Advances AML Therapy and Strengthens Financial Position---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.
Clinical Trial ResultsTUSCANY exhibits initial signs of promise in newly diagnosed AML, with initial safety and efficacy data showing favorable outcomes.
Financial PositionThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.
Bears Say
Funding NeedsAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement designed to provide necessary additional funding and accelerate clinical development.
---
Options Prices
Currently, No data available
---
Ownership Overview
33.30% Insiders
<0.01%
Mutual Funds
6.36% Other Institutional Investors
66.70% Public Companies and
Individual Investors
APS FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was C$1.98 and its highest was C$60.90 in the past 12 months.
What is Aptose Biosciences’s market cap?
Aptose Biosciences’s market cap is $7.43M.
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is May 12, 2025 which is in 28 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on Mar 28, 2025. The company reported -C$13.197 earnings per share for the quarter, missing the consensus estimate of -C$9.392 by -C$3.805.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate is -3.7.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 2,552,429 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of -C$13.197 in its last earnings report, missing expectations of -C$9.392. Following the earnings report the stock price went down -11.418%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Currently, no hedge funds are holding shares in TSE:APS
---
Company Description
Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
---
APS Stock 12 Month Forecast
Average Price Target
C$12.89
▲(342.81% Upside)
Technical Analysis
Oncolytics Biotech
―
Knight Therapeutics
―
Cardiol Therapeutics
―
Quantum Numbers
―
Best Analysts Covering APS
1 Year
1 Year Success Rate
1/18 ratings generated profit
1 Year Average Return
-61.19%
reiterated a buy rating 11 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 5.56% of your transactions generating a profit, with an average return of -61.19% per trade.
---